Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Inclusion Criteria: * Histologically or cytologically confirmed epithelial ovarian, fallopian tube or peritoneal cancer * Recurrent or refractory disease * Measurable disease, defined by RECIST * 0 to 3 prior cytotoxic chemotherapy or biologic regimens for metastatic disease * Adverse events related to prior tumor-specific therapy must have resolved to less than or equal to grade 1 prior to study entry * Ability to swallow oral medications * 18 years of age or older * ECOG Performance status must be 0-2 * Normal organ and marrow function as outlined in the protocol Exclusion Criteria: * Receiving systemic therapy less than 14 days prior to starting sunitinib * Receiving any other investigational agent * Received prior sunitinib * Untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on screening CT or MRI scans * Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism. * Evidence of a bleeding diathesis. Major surgery or NCI CTCA 3.0 grade 3 or worse hemorrhage within 4 weeks of starting study treatment * Ongoing cardiac dysrhythmias of NCI CTCAE version 3.0 grade \> 2 * Pre-existing thyroid abnormality, with thyroid function tests that cannot be maintained in the normal range with medication * Prolonged QTc interval on baseline EKG * Uncontrolled hypertension * Patients who are taking cytochrome P450 enzyme-inducing antiepileptic drugs, rifampin, theophylline, ketoconazole, or St. John's wort. * Psychiatric illness or social situations that wold limit compliance with study requirements * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration * Pregnant women * Clinical or radiographical evidence of a small bowel obstruction * Poor oral intake